Skip to contentD
DiaMedica Therapeutics Inc.
D
DMACDiaMedica Therapeutics Inc. Released Nov 12, 2025, after the close
10-Q filed Nov 12, 2025, 43 days after period end · 0001437749-25-034469
Q3 2025 · 10-Q
Revenue—
Net Income-$8.62M-$8.62MN/M vs Q3 2024N/M vs Q2 2025 EPS, diluted
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
DiaMedica Therapeutics Inc. · CIK 1401040 · Engraved from SEC EDGAR
—
Operating Income-$9,033,000N/M Operating Cash Flowderived-$6,550,000N/M Free Cash Flowderived-$6,566,000N/M ended Sep 30, 2025 · filed Nov 12, 2025 · 43 d after period end
13.9% from the close of Nov 12, 2025 to the close of Nov 13, 2025, the first after the release.
after the close$6.30$5.42 Oct 22Nov 12Dec 5